Pharmacology articles

Cilostazol reduces restenosis in infrapopliteal angioplasty

Cilostazol reduces restenosis in infrapopliteal angioplasty

Original title: Impact of Cilostazol on Angiographic Restenosis after Balloon Angioplasty for Infrapopliteal Artery Disease in Patients with Critical Limb Ischemia Reference: Y. Soga et al. European Journal of Vascular and Endovascular Surgery 44 (2012) 577e581. Angioplasty is regularly used for patients with critical limb ischemia where restenosis is a great limitation, especially in infrapopliteal territory.  The use

High-dose atorvastatin for prevention of contrast nephropathy

Original title: Impact of a High Loading Dose of Atorvastatin on Contrast-Induced Acute Kidney Injury. Reference: Quintavalle et al. CIRCULATIONAHA.112.10331, 2012 Patients included in this study represent a subgroup with chronic renal failure (CRF) enrolled in the NAPLES II trial who were randomized to atorvastatin 80 mg 24 hours before angioplasty, (n = 202) versus the control group

To discontinue clopidogrel after a year of infarction can be risky

Reference: Charlot et al. European Heart Journal 2012 (in press). International guideline recommendations approve giving dual antiplatelet therapy for a period of not less than 12 months after acute myocardial infarction. However, the benefit is unknown if the therapy is extended beyond 12 months. Perhaps its extension could be particularly useful in patients receiving pharmacological

Percutaneous closure of the appendage: results, evidence, team training.

Our editors talked with Dr. Aníbal Damonte Percutaneous closure of left atrial appendage is now a practice that is becoming more topical with a view to results and perspectives. In this regard, we interviewed Dr. Aníbal Damonte, interventional cardiologist at the Cardiovascular Institute of Rosario (Rosario, Argentina).  WEB SOLACI: May I first ask you to

In patients with stroke history, Ticagrelor is superior to Clopidogrel

James SK, Storey RF, Khurmi N, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012. A sub-analysis of the PLATO study demonstrated similar superiority and the safety of ticagrelor in all patients, regardless of any previous history of stroke. Ticagrelor versus clopidogrel:

Six Months Sufficient for Dual Antiplatelet Therapy

Reference: Kandzari DE, Barrer CS, Leon MB, et al. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. JACC Cardiovasc Interv 2011; 4: 1119-28.2011; 4: 1119-28. Patients treated with zotarolimus-eluting stents (ZES) suffer no excess late ischemic events if they take dual antiplatelet therapy for 6 months instead of 12 months or longer,

Ticagrelor vs. Clopidogrel in ST elevation MI: Pros and cons

Platelet Inhibition in the PLATO study: insights from the ECG substudy. En el Estudio PLATO quedó evidenciado que el Ticagrelor disminuyó la mortalidad a 12 meses en comparación con el Clopidogrel en el tratamiento de pacientes post-angioplastía por un síndrome coronario agudo o por un cuadro estable (4,5 vs. 5,9%; P<0.001). Estos resultados fueron del

Top